244 related articles for article (PubMed ID: 27334609)
1. Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET.
Hofheinz F; Hoff Jv; Steffen IG; Lougovski A; Ego K; Amthauer H; Apostolova I
EJNMMI Res; 2016 Dec; 6(1):53. PubMed ID: 27334609
[TBL] [Abstract][Full Text] [Related]
2. An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET.
Hofheinz F; Bütof R; Apostolova I; Zöphel K; Steffen IG; Amthauer H; Kotzerke J; Baumann M; van den Hoff J
EJNMMI Res; 2016 Dec; 6(1):19. PubMed ID: 26936768
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J
J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549
[TBL] [Abstract][Full Text] [Related]
4. Correction of scan time dependence of standard uptake values in oncological PET.
van den Hoff J; Lougovski A; Schramm G; Maus J; Oehme L; Petr J; Beuthien-Baumann B; Kotzerke J; Hofheinz F
EJNMMI Res; 2014 Apr; 4(1):18. PubMed ID: 24693879
[TBL] [Abstract][Full Text] [Related]
5. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
[TBL] [Abstract][Full Text] [Related]
7. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG.
van den Hoff J; Oehme L; Schramm G; Maus J; Lougovski A; Petr J; Beuthien-Baumann B; Hofheinz F
EJNMMI Res; 2013 Nov; 3(1):77. PubMed ID: 24267032
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET.
Hofheinz F; Maus J; Zschaeck S; Rogasch J; Schramm G; Oehme L; Apostolova I; Kotzerke J; den Hoff JV
EJNMMI Res; 2019 Mar; 9(1):23. PubMed ID: 30830508
[TBL] [Abstract][Full Text] [Related]
10. Generation of parametric K
Wu J; Liu H; Ye Q; Gallezot JD; Naganawa M; Miao T; Lu Y; Chen MK; Esserman DA; Kyriakides TC; Carson RE; Liu C
Med Phys; 2021 Sep; 48(9):5219-5231. PubMed ID: 34287939
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma.
Bütof R; Hofheinz F; Zöphel K; Schmollack J; Jentsch C; Zschaeck S; Kotzerke J; van den Hoff J; Baumann M
J Nucl Med; 2018 Aug; 60(2):192-8. PubMed ID: 30166358
[TBL] [Abstract][Full Text] [Related]
12. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
13. A convolutional neural network for fully automated blood SUV determination to facilitate SUR computation in oncological FDG-PET.
Nikulin P; Hofheinz F; Maus J; Li Y; Bütof R; Lange C; Furth C; Zschaeck S; Kreissl MC; Kotzerke J; van den Hoff J
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):995-1004. PubMed ID: 33006022
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Static and Dynamic
Braune A; Hofheinz F; Bluth T; Kiss T; Wittenstein J; Scharffenberg M; Kotzerke J; Gama de Abreu M
J Nucl Med; 2019 Nov; 60(11):1629-1634. PubMed ID: 31053684
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Dual time point based quantification of metabolic uptake rates in 18F-FDG PET.
den Hoff Jv; Hofheinz F; Oehme L; Schramm G; Langner J; Beuthien-Baumann B; Steinbach J; Kotzerke J
EJNMMI Res; 2013 Mar; 3(1):16. PubMed ID: 23497553
[TBL] [Abstract][Full Text] [Related]
18. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of
van den Bosch S; Dijkema T; Philippens MEP; Terhaard CHJ; Hoebers FJP; Kaanders JHAM; Oyen WJG
Radiother Oncol; 2019 Jan; 130():39-45. PubMed ID: 30005954
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
20. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
